FinnGen research project is an expedition to the frontier of genomics and medicine

We are excited to announce the latest public release of FinnGen results and summary statistics!

Follow these instructions to access the data

FinnGen brings together the nation-wide network of Finnish biobanks.

Every Finn can be a part of the FinnGen study by giving a biobank consent.

Samples available

462 000

Samples needed by 2023: 500 000

Current data freeze

321 300

combined genotype and health registry data

Samples from biobanks

The FinnGen study will utilise samples collected by a nationwide network of Finnish biobanks. The study is based on combining genome information with digital health care data from national health registries.

Take part

Samples are needed from all over Finland in the thousands, because solutions in the field of personalized healthcare can be found only by looking at large masses. Every Finn can be a part of the FinnGen study by giving a biobank consent.

Everybody benefits

The genome data produced during the project will be owned by the Finnish biobanks, and remain available for researcher purposes. The medical breakthroughs that arise from the project will eventually benefit health care systems and patients globally.

Collaboration is the key

The collaborative nature of the FinnGen research project is exceptional compared to many other studies. The study involves all the same actors as drug development. With this open cooperation, we hope to speed up the emergence of new innovations.

Data freeze 5 results and summary statistics available!

Results can be browsed online using the FinnGen web browser and the summary statistics downloaded

This data freeze consists of >218,700 individuals, almost 17 M variants and >2,800 disease endpoints. To get more information about how to access the results and summary statistics, please follow this link:

Access results

News

Novel genomic tools increase the accuracy of breast cancer risk assessment

Findings from the FinnGen study encompassing 120,000 women indicate that inherited breast cancer risk should be assessed in an increasingly comprehensive manner. Currently, only individual gene mutations are taken into consideration in breast cancer therapy and prevention. The study demonstrates that more extensive genomic data can be used to identify women who are at high risk of breast cancer with considerably greater accuracy. Such knowledge can especially improve risk assessment among the close relatives of breast cancer patients.

14.12.2020

FinnGen contributes to COVID-19 host genetics initiative

Insights into how to better understand and treat COVID-19 are desperately needed. Given the importance and urgency in obtaining these insights, it is critical for the scientific community to come together around this shared purpose.

30.4.2020

Tweets by FinnGen_FI